biote (NASDAQ:BTMD) Trading 1.1% Higher – Here’s What Happened

by · The Cerbat Gem

biote Corp. (NASDAQ:BTMD – Get Free Report)’s stock price rose 1.1% during trading on Friday . The company traded as high as $2.80 and last traded at $2.78. Approximately 205,213 shares traded hands during mid-day trading, an increase of 87% from the average daily volume of 109,696 shares. The stock had previously closed at $2.75.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BTMD shares. Weiss Ratings reissued a “sell (d+)” rating on shares of biote in a report on Monday, December 15th. Wall Street Zen downgraded biote from a “buy” rating to a “hold” rating in a research note on Sunday, November 2nd. Finally, B. Riley reiterated a “neutral” rating on shares of biote in a research note on Thursday, November 6th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.

Read Our Latest Stock Analysis on biote

biote Stock Performance

The company has a market cap of $126.93 million, a P/E ratio of 3.52 and a beta of 1.15. The stock has a 50-day moving average of $2.71 and a two-hundred day moving average of $3.29.

biote (NASDAQ:BTMD – Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.17. biote had a net margin of 14.72% and a negative return on equity of 21.86%. The business had revenue of $47.96 million during the quarter, compared to the consensus estimate of $47.76 million. As a group, sell-side analysts forecast that biote Corp. will post 0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On biote

Large investors have recently bought and sold shares of the stock. Fisher Asset Management LLC purchased a new stake in shares of biote during the third quarter valued at approximately $30,000. CWM LLC raised its holdings in biote by 952.7% during the 2nd quarter. CWM LLC now owns 8,674 shares of the company’s stock valued at $35,000 after buying an additional 7,850 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in biote during the 2nd quarter valued at $41,000. Hsbc Holdings PLC bought a new stake in biote in the 1st quarter worth $43,000. Finally, AQR Capital Management LLC bought a new stake in biote in the 1st quarter worth $43,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

biote Company Profile

(Get Free Report)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

See Also